Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on RVNC. HC Wainwright reiterated a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Mizuho lowered their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th. Finally, Barclays dropped their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Price Performance

NASDAQ RVNC opened at $3.29 on Monday. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.56. The firm’s 50 day moving average is $3.56 and its 200-day moving average is $4.55. The company has a market capitalization of $343.44 million, a PE ratio of -1.70 and a beta of 0.86.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. As a group, sell-side analysts expect that Revance Therapeutics will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. FORA Capital LLC bought a new stake in shares of Revance Therapeutics during the 3rd quarter worth $54,000. Creative Planning bought a new position in shares of Revance Therapeutics during the third quarter worth about $56,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Revance Therapeutics in the 2nd quarter worth approximately $33,000. Accredited Investors Inc. bought a new stake in Revance Therapeutics during the third quarter valued at $67,000. Finally, Hsbc Holdings PLC acquired a new stake in Revance Therapeutics during the second quarter worth approximately $38,000. Institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.